These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36740773)

  • 21. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
    Unger T; Paulis L; Sica DA
    Eur Heart J; 2011 Nov; 32(22):2739-47. PubMed ID: 21951628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Redefining primary hyperaldosteronism as "The Syndrome of Inappropriate Aldosterone Secretion (SIALDS)": A common but unrecognized cause of hypertension.
    Lamba R
    J Clin Hypertens (Greenwich); 2023 Dec; 25(12):1045-1052. PubMed ID: 37877173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stress-induced Aldosterone Hyper-Secretion in a Substantial Subset of Patients With Essential Hypertension.
    Markou A; Sertedaki A; Kaltsas G; Androulakis II; Marakaki C; Pappa T; Gouli A; Papanastasiou L; Fountoulakis S; Zacharoulis A; Karavidas A; Ragkou D; Charmandari E; Chrousos GP; Piaditis GP
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2857-64. PubMed ID: 25974737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant Hypertension and Bilateral Primary Aldosteronism.
    Murai S; Kakeshita K; Imamura T; Koike T; Fujioka H; Yamazaki H; Kinugawa K
    Intern Med; 2023 Sep; 62(18):2675-2680. PubMed ID: 36725041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic alterations in patients with primary aldosteronism.
    Takeda Y
    Hypertens Res; 2001 Sep; 24(5):469-74. PubMed ID: 11675938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of successful outcome in patients with primary aldosteronism.
    Moo TA; Zarnegar R; Duh QY
    Curr Treat Options Oncol; 2007 Aug; 8(4):314-21. PubMed ID: 18058076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new presentation of the chimeric CYP11B1/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern.
    Carvajal CA; Campino C; Martinez-Aguayo A; Tichauer JE; Bancalari R; Valdivia C; Trejo P; Aglony M; Baudrand R; Lagos CF; Mellado C; Garcia H; Fardella CE
    Hypertension; 2012 Jan; 59(1):85-91. PubMed ID: 22083159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Chinese pedigree with glucocorticoid remediable aldosteronism.
    Liu X; Jin L; Zhang H; Ma W; Song L; Zhou X; Cai J
    Hypertens Res; 2021 Nov; 44(11):1428-1433. PubMed ID: 34462604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension.
    Ardhanari S; Kannuswamy R; Chaudhary K; Lockette W; Whaley-Connell A
    Adv Chronic Kidney Dis; 2015 May; 22(3):185-95. PubMed ID: 25908467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary aldosteronism: Treatment of the disease, and new therapeutic approaches.
    Funder J
    Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101368. PubMed ID: 31813785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New genetic insights in familial hyperaldosteronism.
    Jackson RV; Lafferty A; Torpy DJ; Stratakis C
    Ann N Y Acad Sci; 2002 Sep; 970():77-88. PubMed ID: 12381543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial hyperaldosteronism.
    Torpy DJ; Stratakis CA; Chrousos GP
    Braz J Med Biol Res; 2000 Oct; 33(10):1149-55. PubMed ID: 11004715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat.
    Feldman RD; Sanjanwala R; Padwal R; Leung AA
    Can J Cardiol; 2023 Dec; 39(12):1808-1815. PubMed ID: 37734710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some considerations about evolution of idiopathic primary aldosteronism.
    Armanini D; Fiore C
    J Endocrinol Invest; 2009 Jul; 32(7):623-5. PubMed ID: 19893360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and functional role of the prorenin receptor in the human adrenocortical zona glomerulosa and in primary aldosteronism.
    Recarti C; Seccia TM; Caroccia B; Gonzales-Campos A; Ceolotto G; Lenzini L; Petrelli L; Belloni AS; Rainey WE; Nussberger J; Rossi GP
    J Hypertens; 2015 May; 33(5):1014-22. PubMed ID: 25668351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?
    Lim PO; Struthers AD; MacDonald TM
    J Hypertens; 2002 Jan; 20(1):11-5. PubMed ID: 11791020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.